Boston Scientific Corp (BSX) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Boston Scientific Corp (BSX)

42.68

-0.80 (1.84%)

as of Jun 30, 2026, 8:00:00 pm Market Open.

101 watching

Investor Insights

Jun 30, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Boston Scientific Corp (BSX-N) has been experiencing challenges lately, with a notable decline in stock performance since 2025, breaking critical support levels and exhibiting technical weaknesses as it currently trades below its 200-day moving average. Organic growth has been subpar, as the company recently cut guidance from projected rates, which has contributed to a lack of investor confidence. While the firm is recognized as a leading player in the medical device sector, specifically in non-invasive heart instrumentation, competition has intensified, leading to market share losses against bigger players like Medtronic and Abbott. Despite a strong long-term outlook fueled by aging demographics and increasing demand for cardiovascular procedures, analysts are cautious, recommending a wait-and-see approach as the current valuation appears too high. Overall, Boston Scientific remains a quality organization within its sector, but near-term uncertainties warrant skepticism.

Consensus

Sell

Valuation

Overvalued

Similar

MDT

PAST TOP PICK

(A Top Pick Jul 14/20, Up 23%) It had a couple of disappointing news items involving a couple of their products. They are playing catch-up on elective surgeries. It is one he really likes and continues to hold.

Wealthica Track your Stocks in your Watch List

TOP PICK

It is a medical device company and people are starting to be able to get in to see their doctor and take care of things. A lot of their revenues are tied to non-deferrable procedures. That is positive for the whole group and they have company-specific catalysts also. (Analysts’ price target is $49.00)

HOLD

Looking at the longer term chart, they had a dip around the time China announced first cases of covid. Underperformed relative to others, like other mid-tech companies. Lots of procedures were delayed in hospitals. Now there will be catch up for this. At these levels, there is still some room to run. Could go to $48 range.

BUY

Hit a 52-week high today. This sector (medical devices) has reported very strong reports, such as Intuitive Surgical.

DON'T BUY

Liked it better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Good management that will learn from the past. Volumes in medical devices are not recovering as he expected. He owns Abbott Labs instead, a diversified player with a very strong balance sheet. You could also look at the dental space.

HOLD

Cardiovascular-related devices, and they're doing very well. Raised equity, and pulled a device from market due to potential safety issues. Took a bit of a hit on earnings. Likes it, but he's watching closely as it becomes more concentrated.

TOP PICK

One of the largest medical device manufacturers. New management has cleaned things up. Stock hit by a heart valve recall. Substantial upside. No dividend. (Analysts’ price target is $42.96)

BUY

It has been impacted. From 2013 to 2019 they could do no wrong, then there were a few hiccups. They discontinued one of their hard-valve products that will impact their growth over the next 3-4 years. If you think management can continue to execute and hit a couple of home runs, then stick with it. He would consider it a buy at these levels.

BUY

BSX vs. BDX Owns Boston Scientific instead of BDX. BSX has a strong history of execution. One-time events threw off that execution. Hospital procedures are coming back, which will benefit the entire industry. Well known for innovation.

BUY

Allan Tong’s Discover Picks It trades at a 32x PE, but pays no dividend. Despite the spring lockdown, BSX offers revenue growth YOY of 9.28% though the one-year total return is -5.42%. It beat EPS in three of its last four earnings periods, and the market expects its EPS to leap from 8 cents in Q2 to 24 cents in Q3 (to reported on Oct. 21). Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.

BUY

BSX vs. CCI One of his biggest holdings and fully believes in it. They suffered because their medical devices are non-essential, but they will recover nicely in time. Crown Castle is very different, a real estate play for cell phone towers, which will see strong growth, but the PE is very high given this expected growth. There's little risk though. You can buy both stocks.

TOP PICK

One of the fastest-growiong medical device companies. This has been unfairly beaten up during the pandemic with a delay in elective surgeries. When those operations return, BSX should do well. (Analysts’ price target is $42.96)

COMMENT

Had an exceptional 10 years. Sold off heavily with the coronavirus. High growth. Challenge is you couldn't buy it if you were a value investor. Supply of components will be an issue, as for all its peers.

TOP PICK

They make global medical devices. A steady eddy pick and a good way to play healthcare. Their Q4 report sucked, so the stock sold off, but this has outperformed the medical devices and healthcare indexes before Q4. Q4 was a hiccup, so it's now a buying opportunity or around $40. (Analysts’ price target is $49.14)

BUY ON WEAKNESS

Changing demographics? He has a model price of $45.83 per share -- right around current prices. A move higher in the market could take it to $61. He would wait thru the next earnings announcement. It is not cheap here. He would wait for a pullback before buying in.

Showing 31 to 45 of 72 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Murray

The Murray Wealth Group

Joe Terranova

Virtus Investment Partners

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)